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Objectives We sought to assess the risk of ischemic stroke from a patent foramen ovale (PFO) in the multiethnic prospec-
tive cohort of northern Manhattan.
Background Patent foramen ovale has been associated with increased risk of ischemic stroke, mainly in case-control studies.
The actual PFO-related stroke risk in the general population is unclear.
Methods The presence of PFO was assessed at baseline by using transthoracic 2-dimensional echocardiography with con-
trast injection in 1,100 stroke-free subjects older than 39 years of age (mean age 68.7  10.0 years) from the
Northern Manhattan Study (NOMAS). The presence of atrial septal aneurysm (ASA) also was recorded. Subjects
were followed annually for outcomes. We assessed PFO/ASA-related stroke risk after adjusting for established
stroke risk factors.
Results We detected PFO in 164 subjects (14.9%); ASA was present in 27 subjects (2.5%) and associated with PFO in
19 subjects. During a mean follow-up of 79.7  28.0 months, an ischemic stroke occurred in 68 subjects
(6.2%). After adjustment for demographics and risk factors, PFO was not found to be significantly associated
with stroke (hazard ratio 1.64, 95% confidence interval [CI] 0.87 to 3.09). The same trend was observed in all
age, gender, and race-ethnic subgroups. The coexistence of PFO and ASA did not increase the stroke risk (ad-
justed hazard ratio 1.25, 95% CI 0.17 to 9.24). Isolated ASA was associated with elevated stroke incidence (2 of
8, or 25%; adjusted hazard ratio 3.66, 95% CI 0.88 to 15.30).
Conclusions Patent foramen ovale, alone or together with ASA, was not associated with an increased stroke risk in this multi-
ethnic cohort. The independent role of ASA needs further assessment in appositely designed and powered
studies. (J Am Coll Cardiol 2007;49:797–802) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.08.063H
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cn recent years, the presence of a patent foramen ovale
PFO) has been shown to be associated with an increased
isk of ischemic stroke (1–4). The association has been
redominantly shown in younger patients with unexplained
cryptogenic) stroke but also has been suggested in older
atients (4). The increased stroke risk, mainly demonstrated
y case-control studies, has led to the application of differ-
nt strategies to prevent recurrent events. Medical treatment
sing antiplatelet agents or systemic anticoagulation (5–7),
pen heart surgery (8–10), and transcatheter PFO closure
11–16) have all been shown to be effective in reducing the
isk of recurrent events in stroke patients with a PFO.
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t the Sergievsky Center, and §Biostatistics, Columbia University Medical Center,
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merican Heart Association Stroke International Conference, Phoenix, Arizona.i
Manuscript received June 27, 2006; revised manuscript received August 11, 2006,
ccepted August 14, 2006.owever, the risk of first ischemic stroke associated with a
FO in prospective population-based cohorts is not well
stablished. Such information is of crucial importance, given
he high prevalence of PFO in the population (approxi-
ately 25%) (17,18). Therefore, the purpose of the present
tudy was to evaluate prospectively the risk of ischemic
troke associated with the presence of a PFO in the
ultiethnic cohort of northern Manhattan. The role of an
ssociated atrial septal aneurysm (ASA), which has also
een associated with stroke risk (19,20), was also evaluated.
ethods
he study cohort was derived from the NOMAS (Northern
anhattan Study), an epidemiological study that evaluates
he incidence, risk factors, and clinical outcome of stroke in
he multiethnic population of northern Manhattan. The
tudy design and other methodological details regarding
OMAS have been described previously (21). In brief,
ommunity subjects from northern Manhattan were eligible
f they: 1) had never been diagnosed with a stroke, 2) were
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resided in northern Manhattan
for at least 3 months in a house-
hold with a telephone. Stroke-
free subjects were identified by
random digit dialing using dual-
frame sampling to identify both
published and unpublished tele-
phone numbers. Of the prospec-
tive study participants that were
contacted telephonically, 90%
greed to come in for an in-person visit. Of those, 75%
greed to be enrolled in NOMAS and undergo the echo-
ardiographic testing.
From May 24, 1993, through November 11, 1999, 1,148
troke-free subjects underwent transthoracic echocardiogra-
hy with contrast injection as part of NOMAS. Echocar-
iographic contrast study was technically inadequate in 47
ubjects (4.1%). No follow-up information could be ob-
ained in 1 additional subject. Therefore, this article reports
n results obtained in 1,100 subjects.
All study subjects provided informed consent. The study
as approved by the Institutional Review Board of Colum-
ia University Medical Center.
iagnostic evaluation. Data were collected through inter-
iew, review of the medical records, physical and neurolog-
cal examination by the study physicians, in-person mea-
urements, and fasting blood specimen drawing. Routine
aboratory tests included complete blood counts, coagula-
ion studies, serum electrolytes, liver function tests, glucose,
nd cholesterol determination. Arterial hypertension was
efined as the presence of a positive history or antihyper-
ensive treatment, or blood pressure values 140/90 mm
g during the interview. Hypercholesterolemia was defined
s a total serum cholesterol 240 mg/dl or the presence of
ppropriate drug treatment. Diabetes mellitus was defined
n the basis of abnormal fasting glucose 125 mg/dl,
ositive history, or the presence of oral or insulin treatment.
oronary artery disease included a history of myocardial
nfarction or typical angina or the patient’s reporting of a
ositive diagnostic test (stress test, coronary angiography)
nd/or drug treatment. The presence of atrial fibrillation
as classified by history (current or past electrocardiography
ECG] or Holter provided by the patient) and also included
he results of an ECG done at the time of enrollment.
chocardiographic evaluation. Transthoracic 2-dimensional
chocardiography was performed in all study subjects ac-
ording to the recommendations of the American Society of
chocardiography. Saline contrast injection (aerated saline
olution) was used for PFO detection (1–3), and Valsalva
aneuver and coughing were used to increase sensitivity
22). A PFO was considered to be present if any micro-
ubble was seen in the left-sided cardiac chambers within 3
ardiac cycles from maximum right atrial opacification
Abbreviations
and Acronyms
ASA  atrial septal
aneurysm
CI  confidence interval
PFO  patent foramen
ovale
TEE  transesophageal
echocardiography1–3). An ASA was defined as more than a 10-mm srotrusion beyond the plane of the septum into the left or
ight atrium (23).
ollow-up and outcome evaluation. All subjects were
ollowed annually by telephone. The proportion of subjects
ho had a follow-up point at 5 years from baseline was 98%
1,078 of 1,100). Any vascular event or acknowledgment of
eurological or cardiac symptoms during the annual stan-
ardized interview triggered an in-person assessment. All
ubjects who screened positive for possible stroke were
ssessed in person by a neurologist. In addition, active
ospital surveillance of admission and discharge Interna-
ional Classification of Diseases-9th revision codes was
erformed. Stroke was defined by the first symptomatic
ccurrence of any type of stroke as defined by TOAST
Trial of ORG 10172 in Acute Stroke Treatment) criteria
24). Diagnosis of ischemic stroke was determined by 2
eurologists independently, and the NOMAS principal
nvestigator (R.L.S.) adjudicated any disagreements. Isch-
mic stroke, fatal and nonfatal, was used as the primary
utcome of the present study. Stroke diagnostic subtypes
embolic vs. nonembolic) were defined by a neurologist
naware of subjects’ PFO status according to modified
troke Data Bank criteria (25).
tatistical analysis. Given the sample size of 1,100 and the
bserved PFO prevalence of 14.9%, the study had 80%
ower to detect a minimum relative risk of 2.08 at a 0.05
ignificance level. Data are presented as mean values 1
tandard deviation for continuous variables and as propor-
ions for categorical variables. Kaplan-Meier event-free
nalysis was performed for ischemic stroke with and without
FO. The difference between groups was evaluated by
eans of the log-rank test. Cox proportional hazards
urvival models were used to assess the risk of stroke from
FO/ASA. Hazard ratios and 95% confidence intervals
CIs) for PFO/ASA and stroke were calculated after ad-
ustment for other stroke risk factors (hypertension, diabe-
es, hypercholesterolemia, cigarette smoking, atrial fibrilla-
ion). To test the effect of age ( vs.60 years), gender and
ace-ethnicity on the association between PFO and stroke,
eparate variables were fit in the model to quantify the effect
f PFO independently for each subgroup. Differences be-
ween subgroups were tested using interaction terms. A p
.05 was considered significant for all analyses. Data were
nalyzed by 1 investigator (R.R.S.) using SAS software
version 9.0, SAS Institute, Cary, North Carolina).
esults
haracteristics of the study cohort. The characteristics of
ubjects are shown in Table 1. Eleven hundred subjects (460
en, 640 women, mean age 68.7  10.0 years) were
nrolled. Twenty-six percent of the population was black,
9.3% was Hispanic, and 24.7% white. Women comprised
ore than 58% of the cohort.
revalence of PFO and ASA. A PFO was detected in 164ubjects (14.9%) (Table 1). An ASA was detected in 27
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haracteristics of subjects with and without a PFO are
ummarized in Table 2. The 2 groups were well balanced
ith respect to demographics and traditional stroke risk
actors, with the only significant difference being a lower
roportion of subjects with hypertension in the PFO group.
spirin usage for non–PFO-related indications (recorded
or its potential effect on stroke risk) was not significantly
ifferent between the 2 groups.
FO, ASA, and the risk of ischemic stroke. Subjects
ere followed for a mean duration of 79.7  28.0 months
range 43 to 135 months). During the follow-up, an
emographics, Risk Factors,nd Atri l Septal Abnormalities
Table 1 Demographics, Risk Factors,and Atrial Septal Abnormalities
Overall Cohort (n  1,100)
Age, yrs (mean  SD) 68.7 10.0
Male 460 (41.8%)
Race
Black 281 (26.0%)
Hispanic 532 (49.3%)
White 266 (24.7%)
Risk factors
Hypertension 740 (67.3%)
Hypercholesterolemia 497 (45.2%)
Atrial fibrillation 28 (2.6%)
Diabetes mellitus 244 (22.2%)
Ever smoked 588 (53.5%)
Current smoker 183 (16.9%)
Atrial septal abnormalities
PFO 164 (14.9%)
ASA 27 (2.5%)
PFO  ASA 19 (1.7%)
Aspirin usage 285 (25.9%)
SA  atrial septal aneurysm; PFO  patent foramen ovale.
emographics, Risk Factors,nd Aspirin U age by PFO Status
Table 2 Demographics, Risk Factors,and Aspirin Usage by PFO Status
PFO 
(n  164)
PFO 
(n  936) p Value
Age, yrs (mean  SD) 68.4 9.4 68.7 10.1 0.7
Race
Black 44 (27.5%) 237 (25.8%) 0.68
Hispanic 78 (48.8%) 454 (49.4%) 0.82
White 38 (23.8%) 228 (24.8%) 0.74
Gender
Female 87 (53.0%) 553 (59.1%) 0.15
Male 77 (47.0%) 383 (40.9%) 0.15
Risk factors
Hypertension 99 (60.4%) 641 (68.5%) 0.04
Hypercholesterolemia 68 (41.5%) 429 (45.8%) 0.3
Atrial fibrillation 5 (3.1%) 23 (2.5%) 0.66
Diabetes mellitus 30 (18.3%) 214 (22.9%) 0.19
Ever smoked 91 (55.5%) 497 (53.1%) 0.57
Current smoker 36 (22.2%) 147 (16.0%) 0.05
Aspirin usage 41 (25.0%) 244 (26.2) 0.75FO  patent foramen ovale. fschemic stroke occurred in 68 subjects (6.2%). Stroke
ncidence was 12.2 per 1,000 person-years in subjects with a
FO and 8.9 per 1,000 person-years in those without it
p  0.5). Figure 1 shows the stroke-free survival in the 2
roups. The curves of subjects with and without PFO did
ot differ significantly (p  0.28). After adjustments for
ther stroke risk factors, the hazard ratio of PFO for stroke
as 1.64 (95% CI 0.87 to 3.09) (Table 3). The frequency of
ryptogenic stroke was not significantly different between
troke patients with a PFO and those without it (18.2% vs.
1.2%; p  0.6), and so was the frequency of embolic
trokes (18.2% vs. 32.7%; p  0.3).
The analysis of the stroke risk associated with an ASA, alone
r in combination with a PFO, was hindered by the small
umber of subjects with this finding (n  27). The coexist-
nce of PFO and ASA was not found to increase the risk of
troke (Table 3). The few subjects with an isolated ASA
howed an elevated risk of stroke (2 of 8, or 25%), but isolated
SA was not independently associated with stroke (adjusted
azard ratio 3.66, 95% CI 0.88 to 15.30) (Table 3).
ffect of age, gender, and race-ethnicity. The lack of a
ignificant association between PFO and stroke was ob-
Figure 1 PFO and Risk of Ischemic Stroke
Kaplan-Meier estimate of stroke-free survival according
to baseline patent foramen ovale (PFO) status.
isk of Ischemic Stroke by PFO/ASA Status
Table 3 Risk of Ischemic Stroke by PFO/ASA Status
Unadjusted HR
(95% CI)
Adjusted HR*
(95% CI)
PFO (regardless of ASA
presence)
1.39 (0.75–2.61) 1.64 (0.87–3.09)
PFO alone 1.51 (0.79–2.90) 1.79 (0.93–3.45)
PFO  ASA 0.93 (0.13–6.69) 1.04 (0.14–7.74)
ASA alone 4.37 (1.06–18.00) 3.66 (0.88–15.30)
Adjusted for age, gender, atrial fibrillation, diabetes mellitus, arterial hypertension, hypercholes-
erolemia, and current smoking.
ASA  atrial septal aneurysm; CI  confidence interval; HR  hazard ratio; PFO  patent
oramen ovale.
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PFO and Stroke Risk in the General Population February 20, 2007:797–802erved in both men and women, and in patients younger or
lder than 60 years of age (Table 4), although with higher
azard ratios in men and in younger subjects. No significant
ssociation between PFO and stroke was observed in any
ace-ethnic subgroups. A similar analysis could not be
erformed for ASA because of the much smaller sample
ize.
iscussion
atent foramen ovale and ischemic stroke. The present
tudy shows no significant increase in the risk of ischemic
troke from a PFO in the general population during a mean
ollow-up of almost 7 years. This observation has great
ractical importance because a PFO is found in approxi-
ately one-quarter of the general population. The lack of an
ncrease in risk was consistent across all age, gender, and
ace-ethnic subgroups analyzed. A PFO has been shown in
he past by us and others to be associated with ischemic
troke, especially cryptogenic stroke (1–4). Those observa-
ions were made mostly in case-control studies, which
aired subjects in whom a stroke had already occurred with
troke-free controls of same gender and similar age. Besides
he possibility of selection and referral bias (26,27), those
ase-control studies only established an increased prevalence
f PFO among stroke patients but were unable to evaluate
he magnitude of the PFO-related stroke risk in the general
opulation. Our study demonstrates that this absolute risk is
ow, at least over the period of observation considered.
hese 2 findings may not be as discordant as they appear.
lthough far from reaching statistical significance, the
resence of a PFO in our study carried a not entirely
egligible adjusted hazard ratio for stroke of 1.64. More-
ver, the hazard ratios were slightly greater for men and for
ubjects younger than 60 years of age. It is possible that this
light increase in risk may stem from a minority of patients
ho are indeed at higher risk but whose influence on the
verall trend would be diluted because of their relatively
mall number.
Although our data suggest that the absolute risk of stroke
rom a PFO in the general population is low, the search may
ssociation Between PFO and Ischemictroke by Gender, Age, and Race-Ethni ity
Table 4 Association Between PFO and IschemicStroke by Gender, Age, and Race-Ethnicity
Unadjusted HR
(95% CI)
Adjusted HR*
(95% CI)
Male 1.74 (0.74–4.09) 2.00 (0.84–4.74)
Female 1.09 (0.43–2.80) 1.34 (0.52–3.44)
Age 60 yrs 2.35 (0.53–10.37) 3.41 (0.76–15.25)
Age 60 yrs 1.34 (0.68–2.64) 1.49 (0.76–2.95)
Black 1.33 (0.45–3.90) 1.60 (0.54–4.76)
Hispanic 1.45 (0.55–3.83) 1.78 (0.67–4.73)
White 1.39 (0.40–4.87) 1.51 (0.43–5.34)
Adjusted for age, gender, atrial fibrillation, diabetes mellitus, arterial hypertension, hypercholes-
erolemia, and current smoking.
Abbreviations as in Table 3.till be on for individual subjects in whom PFO carries an pncreased risk, possibly because of associated cofactors that
ay turn a PFO from an innocent bystander into a causative
echanism for stroke. The studies that documented an
ncreased risk of stroke from a PFO in the past may have
ncluded a much larger proportion of these subjects, because
hey were all conducted on stroke patients, either because of
heir case-control design (1–4) or because of their focus on
troke recurrence (28). The size of a PFO (29–31), presence
f deep venous thrombosis (32,33), associated right atrial
bnormalities (34), and hypercoagulability (35–38) have all
een cited as possible cofactors in the risk of stroke
ssociated with a PFO. Further research is needed to define
heir role, as well as to investigate the possibility that other
otential cofactors may exist that are yet unknown.
he relationship of ASA and ischemic stroke. Given the
ow prevalence of ASA in the population (1% to 4%)
18,26), our study was not powered to conclusively address
he role of an ASA, alone or in combination with a PFO, on
he stroke risk. However, the combination of PFO and
SA did not appear to increase the stroke risk, which is in
greement with what was recently reported by a similar
tudy (27). Also in agreement with that study, an isolated
SA carried an unusually high incidence of stroke in the
mall number of subjects who had it (2 of 8, or 25%, in our
tudy, and 2 of 5, or 40%, in the other). This finding seems
o oppose the widely held opinion that an ASA is associated
ith stroke via the high frequency of associated PFO, but
annot be considered conclusive because of the small num-
er of subjects analyzed. The possibility that an ASA may
ncrease the risk of stroke through mechanisms other than
FO, such as atrial electrical instability (39) and consequent
ncreased frequency of paroxysmal atrial fibrillation, requires
ssessment in appositely designed studies.
omparison with previous studies. Although a number of
tudies have evaluated the risk of recurrence in stroke
atients with a PFO, only 1 recently published study has
ssessed the PFO-related stroke risk in the general popula-
ion. In 577 subjects undergoing transesophageal echocar-
iography (TEE) as part of the SPARC (Stroke Prevention:
ssessment of Risk in a Community) study, Meissner et al.
27) reported results similar to ours, with an adjusted hazard
atio of PFO and cerebrovascular events of 1.46 (95% CI
.74 to 2.88). Similar conclusions on the PFO-related
troke risk were drawn by the same investigators using a
ase-control design (40). However, some important differ-
nces exist between SPARC and our study. Our sample size
as almost double that of the SPARC study, and our
ollow-up duration was substantially longer. The larger
ample size allowed the analysis of race-ethnic differences in
he role of PFO on stroke risk, information largely missing
n the literature. No patients with stroke/transient ischemic
ttack were present in our cohort at baseline versus 6.3% of
ubjects with a history of cerebrovascular disease or proce-
ures in SPARC. Also, transient ischemic attacks were not
ncluded among our end points, which only included com-
lete strokes with confirmation by computed tomography or
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February 20, 2007:797–802 PFO and Stroke Risk in the General Populationagnetic resonance imaging. The presence of PFO/ASA
as ascertained by TEE in SPARC and by transthoracic
chocardiography in our study. Although TEE is more
ensitive for PFO detection, most of its additional yield
omes from very small PFO with minimal right to left
hunts (41), whose role as a potential stroke risk factor is
uestionable.
trengths and limitations. This study is the largest to date
hat has prospectively assessed the role of PFO/ASA as a
troke risk factor in the general population. The results are
mportant for a more comprehensive view of the relation-
hip between PFO and stroke, as well as to provide context
or the use of the different strategies currently suggested for
troke prevention in subjects with a PFO. The rather large
ample size allowed us to obtain information in different
ace-ethnic groups, which is important in the light of
revious suggestions of different PFO characteristics, and
herefore different risk, among different races (42).
Transthoracic echocardiography was used for PFO de-
ection instead of the more-sensitive TEE. However, TEE
s a semi-invasive technique not suited for use in a low-risk
opulation; therefore, our results may be more relevant to
he reality of a PFO detected as an incidental finding in
eneral practice. Because transthoracic echo does not visu-
lize well the pulmonary veins, some shunts attributed to
FO may in fact have been secondary to intrapulmonary
hunting, although this possibility was greatly reduced by
he early timing of the shunt included in the diagnosis of
FO (within 3 cardiac cycles from right atrial opacification).
onclusions. Our study suggests that the medium-term
isk of stroke associated with a PFO in the general popu-
ation is low and that the relative risk of subjects with a PFO
s not significantly increased in comparison with subjects
ithout it. The possibility that the stroke risk may be
ncreased in a subgroup of subjects, with yet-unidentified
ofactors, cannot be excluded by this study. The stroke risk
ssociated with an ASA requires further evaluation in
ppropriately designed and powered studies.
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